Ładuje się......
Cell-based Immunotherapy Against Gliomas: From Bench to Bedside
Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of brain tumors with a median survival of 18–21 months. Standard-of-care treatment includes maximal surgical resection of the tumor mass in combination with radiation and chemotherapy. However, as the poor survival rate i...
Zapisane w:
| Główni autorzy: | , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Nature Publishing Group
2013
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3702108/ https://ncbi.nlm.nih.gov/pubmed/23648695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2013.80 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|